The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.
A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
Big medtech is keeping its purse-strings closed – but private equity sees value in subsidiaries.
The $6.6bn of M&A deals announced by drug makers in third quarter of 2018 marks the slowest three-month period since 2013.
A return to tuck-in deals – sort of.
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.